DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued on Thursday. The brokerage set a “hold” rating on the stock.

Separately, JMP Securities reissued a “market outperform” rating and set a $10.00 target price on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Performance

Shares of NASDAQ DBVT opened at $4.44 on Thursday. The firm has a fifty day moving average of $4.18 and a 200 day moving average of $3.82. The firm has a market cap of $91.33 million, a PE ratio of -0.99 and a beta of 0.67. DBV Technologies has a one year low of $2.20 and a one year high of $9.09.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent SEC filing. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.